← Eichor
Study identifier: NCT07304843 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

A Two-part Study to Investigate the Effects in Adults of Two Doses of Golexanolone in Patients With Primary Biliary Cholangitis (PBC) With Fatigue and Cognitive Dysfunction

Condition: Primary Biliary Cholangitis (PBC)  ·  Sponsor: Umecrine Cognition AB

PhasePhase 1/Phase 2
Planned participants84
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

The present phase 1b/2 randomised, double-blind, placebo-controlled, two-part study is designed to evaluate the safety, tolerability, pharmacokinetic characteristics and preliminary efficacy of two dose levels of golexanolone compared with placebo among subjects with a history of non-cirrhotic or Child-Pugh class A cirrhotic Primary Biliary Cholangitis (PBC) with clinically significant fatigue and cognitive symptoms on stable background standard of care (SoC) PBC medication. The objectives of this research study are to assess the safety and tolerability as well the pharmacokinetic (PK) characteristics of golexanolone administered 40 mg BID for 5 days in the target population (part A) and to assess the safety and tolerability, the effects of golexanolone on health-related quality of life (HRQoL), including fatigue, day-time sleepiness and cognitive function as well as Investigator's overall impression of treatment effect of 28 days twice per day (BID) treatment with two dose levels of golexanolone versus placebo (part B).

This description comes directly from the study's public registry record.

Talk to the study team

Pernilla Sandwall  ·  +46 70 630 65 19  ·  pernilla.sandwall@umecrine.se

Always discuss trial participation with your own doctor first.

Locations (40)

University Hospital DüsseldorfDüsseldorf, GermanyRecruiting
University of LeipzigLeipzig, GermanyRecruiting
Hippokration General Hospital of AthensAthens, GreeceRecruiting
University Hospital of PatrasPátrai, GreeceRecruiting
Bekes County Central HospitalGyula, HungaryWithdrawn
Facility of CRU Hungary Ltd.Kistarcsa, HungaryCompleted
Università di Milano-Bicocca, S.C. ASST Grande Ospedale Metropolitano Niguarda, Dipartimento di Medicina e Chirurgia, Epatologia e GastroenterologiaMilan, ItalyRecruiting
Fondazione IRCCS San Gerardo dei Tintori, Autoimmune Liver Disease Centre, ERN-Rare Liver, Department of Medicine and Surgery, Division of GastroenterologyMonza, ItalyNot Yet Recruiting
University of Padova, Department of Surgery, Oncology and GastroenterologyPadova, ItalyRecruiting
University Hospital Paolo Giaccone, University of PalermoPalermo, ItalyRecruiting
A. Gemelli Polyclinic, Sacro Cuore Catholic UniversityRoma, ItalyRecruiting
Humanitas UniversityRozzano, ItalyRecruiting

+ 28 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07304843